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Running title: 
Obinutuzumab for treating follicular lymphoma refractory to rituximab 
Abstract 
As part of its Single Technology Appraisal process, the National Institute for Health and Care 
Excellence (NICE) invited the manufacturer of obinutuzumab (Roche) to submit evidence on its 
clinical and cost-effectiveness when used in combination with bendamustine in people with follicular 
lymphoma (FL) refractory to rituximab. The Evidence Review Group, the School of Health and 
Related Research Technology Appraisal Group at the University of Sheffield, produced a document 
summarising the key points from the company submission alongside a critical review. Efficacy for 
progression-free survival (PFS) and safety was positively demonstrated in the pivotal GADOLIN trial 
which compared obinutuzumab in combination with bendamustine followed by obinutuzumab 
maintenance (O-Benda+O) against bendamustine monotherapy. Data on overall survival were 
immature. The company submitted a model-based economic analysis, including a patient access 
scheme. The key uncertainty was the duration of the treatment effect on overall survival. This 
uncertainty is expected to be reduced when the final analysis of the GADOLIN trial is reported. 
Consequently, the NICE appraisal committee recommended O-Benda+O in the population covered by 
the marketing authorisation within the Cancer Drug Fund until NICE is able to review the guidance 
following publication of the final analysis of GADOLIN.  
 
 
Key points for decision makers 
         Obinutuzumab in combination with bendamustine appears to have an acceptable/manageable 
adverse event profile and is efficacious compared with bendamustine monotherapy in reducing the 
risk of progression in people with follicular lymphoma refractory to rituximab. 
        Data on overall survival from the GADOLIN trial were immature 
         Obinutuzumab in combination with bendamustine could be cost-effective compared with 
bendamustine monotherapy in people with follicular lymphoma refractory to rituximab, depending on 
the extent of survival gain 
         The final analysis of GADOLIN will reduce the uncertainty on the extent of overall survival gain 
and produce a more robust cost-effectiveness estimate 
 
 
1. Introduction 
The National Institute for Health and Care Excellence (NICE) is an independent organisation whose 
responsibilities include providing national guidance to the NHS in England and Wales on health 
technologies.[1] The NICE Single Technology Appraisal (STA) process usually covers new single 
health technologies within a single indication, soon after they have received UK marketing 
authorisation.   
 
Within this process, the company submits evidence on the clinical and cost-effectiveness of the 
technology in the form of a written document alongside a mathematical economic model. The 
company submission (CS) is then reviewed by an external independent group, the Evidence Review 
Group (ERG), with advice from clinical specialists. Findings from the ERG are summarised in a report, 
called the ERG report.[2] 
 
Evidence submitted by the company and the ERG report are then considered by the NICE Appraisal 
Committee (AC) alongside testimony from experts and other stakeholders. A Final Appraisal 
Determination (FAD) is produced directly when the intervention is recommended without restriction. 
Otherwise, an Appraisal Consultation Document (ACD) is initially produced, followed by a FAD if the 
recommendations from the NICE AC are restrictive or additional clarification/analyses are required 
from the company. 
 
This paper presents a summary of the ERG report[2] and FAD[3] for the STA of obinutuzumab with 
bendamustine for treating follicular lymphoma refractory to rituximab. This paper also covers the 
subsequent development of the NICE guidance for the use of this drug in England. Full details of all 
relevant appraisal documents can be found on the NICE website.[4] 
 
2. Decision problem  
Follicular lymphoma (FL) is an indolent non-Hodgkin lymphoma (NHL). It is the second most common 
NHL diagnosed in the United States and Western Europe accounting for over 35% of all NHLs and 
70% of indolent lymphomas. The diagnosis of FL is typically confirmed by surgical specimen/biopsy, 
histological report and reviewed by an expert haematologist. The treatment of FL is dependent on the 
stage of the disease usually determined using the Ann Arbor system. 
Indolent NHLs are chronic diseases characterised by repeated relapses requiring treatment and 
periods of disease progression. Standard therapeutic approaches focus on disease control. People 
with indolent lymphomas are usually considered incurable with standard therapeutic approaches. 
The treatment pathway in FL is complex and treatment options are limited after patients become 
refractory to rituximab.[5] Most people needing treatment receive first-line induction treatment with a 
rituximab-containing regimen, followed by rituximab maintenance therapy. Second-line treatment for 
FL depends on the type of regimen used first-line and the timing of relapse following first-line 
treatment. People with FL who do not achieve a response to first-line induction treatment with a 
rituximab-containing regimen are considered to be refractory and would typically receive 
bendamustine monotherapy. The choice of second-line treatment is less clear in people who respond 
to first-line induction treatment with a rituximab-containing regimen, but relapse during, or within 6 
months of completion of maintenance therapy. Typically, patients relapsing early within the 
maintenance phase would be considered refractory to rituximab and would be treated with 
bendamustine monotherapy. People who experience a relapse after some time on maintenance 
treatment with rituximab or at the end of maintenance treatment may not be considered refractory and 
may receive rituximab in combination with an alternative agentas second-line treatment.  
Obinutuzumab is a Type II anti-CD20 antibody that targets the extracellular loop of the CD20 
transmembrane antigen on the surface of non-malignant and malignant pre-B and mature B-
lymphocytes, but not on haematopoietic stem cells, pro-B cells, normal plasma cells or other normal 
tissue. Obinutuzumab is available as a liquid concentrate solution for infusion. Each pack contains 
one vial containing 1,000 mg of obinutuzumab. 
Obinutuzumab is indicated for the treatment of FL patients refractory to rituximab and is given in 
combination with bendamustine as induction treatment (6 cycles of 28-days), followed by a 
maintenance phase with obinutuzumab monotherapy every 2 months for up to two years or until 
progression in people who do not progress at the end of the induction phase. 
3. Independent Evidence Review Group (ERG) Report 
In accordance with the process for STAs, the ERG and NICE had the opportunity to seek clarification 
on specific points in WKHFRPSDQ\¶VVXEPLVVLRQ&6[6] in response to which the company provided 
additional information.[7, 8] 7KH(5*DOVRPRGLILHGWKHFRPSDQ\¶VGHFLsion analytic model to produce 
an ERG base case and to assess the impact of alternative parameter values and assumptions on the 
PRGHO UHVXOWV 7KH HYLGHQFH SUHVHQWHG LQ WKH &6 DQG WKH (5*¶V UHYLHZ RI WKDW HYLGHQFH LV
summarised here. 
 
3.1. Clinical Evidence Provided by the Company 
The CS[6] included a systematic review of the clinical effectiveness literature. The main supporting 
evidence was derived from GADOLIN.[9-14] This study was a company-sponsored, randomised, 
open-label, event-driven, multicentre study designed to compare the efficacy and safety of induction 
therapy with obinutuzumab in combination with bendamustine followed by obinutuzumab 
maintenance therapy (O-benda+O) with bendamustine monotherapy as induction therapy, in 413 
people (57.6% male; 87.4% Caucasian; mean age 62 years) with rituximab-refractory indolent NHL 
(81% had FL [population defined in the marketing authorisation of obinutuzumab] and 19% had non-
FL). 
 
3.1.1. Clinical study design 
GADOLIN [9-14] was a Phase III trial that consisted of three phases, including an induction phase 
(approximately 6 months), a maintenance/follow-up phase (2 years) and an extended follow-up phase 
(2 years). For the induction phase (six 28-day cycles, all treatments given intravenously), people with 
rituximab-refractory indolent NHL (defined as a lack of response during treatment or progression 
within six months following the last dose of rituximab or a rituximab-containing regimen [including 
rituximab monotherapy as part of induction or maintenance treatment]) were randomly allocated to 
receive either obinutuzumab (1,000 mg on days 1, 8 and 15 of Cycle 1; and on day 1 only of Cycles 2 
to 6) in combination with bendamustine (90 mg/m2/day on days 1 and 2 for Cycles 1 to 6; n=204) or 
bendamustine monotherapy (120 mg/m2/day on days 1 and 2 for Cycles 1 to 6; n=209). Patients in 
the obinutuzumab plus bendamustine group without evidence of disease progression (i.e. patients 
with a complete response, partial response or stable disease) following induction received 
obinutuzumab maintenance therapy (1000 mg every 2 months) for up to 2 years. In contrast, as there 
was no equivalent maintenance phase in the bendamustine monotherapy group, these patients 
received no further active treatment (e.g. anti-lymphoma treatments) after completion of the 
bendamustine induction phase and therefore entered the follow-up phase of the study. Thereafter, all 
patients entered a 2 year extended follow-up phase. The primary outcome measure was progression-
free survival (PFS), defined as the time from randomisation to first occurrence of progression or 
relapse, or death from any cause on study, as assessed by an independent review committee (IRC).    
 
The data cut-off for the primary analysis of efficacy and futility was 1st September 2014,[6] which took 
place after 175 IRC-assessed PFS events had occurred. As the primary endpoint had been reached, 
an Independent Data Monitoring Committee recommended that the study be unblinded to the 
Sponsor, fully analysed and the results made public. Additional post-hoc exploratory analyses 
(updated analysis) were conducted based on an additional data cut-off of 1st May 2015.[6] The 
overall median observation time (randomisation to last available assessment) for the FL population at 
the time of the updated clinical cut-off was 24.1 months in both groups. During the appraisal 
consultation period, the company provided revised updated data (with approximately 3 years of 
follow-up to April 2016).[7] However, these data were marked academic-in-confidence and cannot be 
reproduced. 
3.1.2. Clinical study results 
Clinical effectiveness 
Based on analyses of the data available in May 2015,[6] treatment of the FL subgroup (i.e. the main 
target population in the CS, n=335) with O-benda+O was associated with a statistically significant 
improvement in the risk of a PFS event as assessed by the IRC compared with bendamustine 
monotherapy (hazard ratio [HR] = 0.47, 95% CI: 0.34 to 0.64, p<0.0001, stratified log-rank test) 
resulting in an absolute increase in median IRC-assessed PFS of 15.4 months. For other secondary 
endpoints (based on IRC assessments) at the end of the induction period there were no statistically 
significant differences in best overall response rates (p=0.5098) or end-of treatment response rates 
(p=0.6972) between treatment arms. However, the duration of response for patients who achieved a 
complete or partial response and disease-free survival for complete responders in the study were 
reported to be significantly longer in the O-benda+O group (median not reached) compared with the 
bendamustine group (median 11.6 months for duration of response [p= not reported] and 13.0 months 
for disease free survival [p= not reported]). An analysis of event-free survival found that statistically 
fewer patients with FL had an event with O-benda+O compared with bendamustine alone (p<0.001). 
Although overall survival data were not mature at the time of the analysis , statistically fewer patients 
with FL in O-benda+O (18.3% [30/164]) had died compared with FL patients in the bendamustine 
monotherapy group (28.1% [48/171]) at median follow-up of 24.1 months (p=0.0379).  
 
Safety 
Adverse-event data were collected for all patients who had any component of obinutuzumab or 
bendamustine treatment inGADOLIN. At the last data-cut (1st May 2015) (, 98.8% of FL patients in 
both trial arms had at least 1 adverse event (any grade). In the O-Benda+O arm (n=164), 39.0% of 
patients had a serious treatment related adverse event compared with 34.5% in the bendamustine 
monotherapy arm (n=168). The most common serious adverse events were neutropenia (32.3% 
versus 24.4%), infections (15.9% versus 19.6%), thrombocytopenia (11.0% versus 14.9%), infusion 
related reactions (9.1% versus 3.6%) and cardiac events (4.9% versus 1.2%), respectively.[6] 
 
Indirect comparison and/or multiple treatment comparison  
As there was no connected network of evidence, the company were unable to make any indirect 
comparisons with other relevant interventions identified in the scope e.g. chemotherapy regimens 
without rituximab (such as cyclophosphamide- or fludarabine-containing regimens or chlorambucil) or 
best supportive care. 
 
3.2. Critique of the Clinical Evidence and Interpretation 
3.2.1. Critique of systematic review 
The systematic review process followed by the company was reasonably comprehensive. Despite 
PLQRUOLPLWDWLRQVLQWKHFRPSDQ\¶VVHDUFKVWUDWHJ\WKH(5*ZDVFRQILGent that all relevant controlled 
studies of obinutuzumab in combination with bendamustine monotherapy for the treatment of 
rituximab-refractory FL were included in the CS, including data from ongoing or planned studies. 
However, the ERG was not confident that all relevant non-controlled studies had been identified and 
included in the CS, as details of the systematic review process (e.g. identification, selection etc.) were 
lacking in the CS. The specified inclusion and exclusion criteria were mostly appropriate and generally 
reflected the decision problem set out in the final NICE scope.[15] The quality assessment tool used 
to appraise the included GADOLIN study was considered appropriate by the ERG. 
 
3.2.2. Critique of clinical evidence 
Although the efficacy of obinutuzumab in combination with bendamustine compared with 
bendamustine monotherapy in GADOLIN appeared favourable, and the safety appeared acceptable, 
there were a number of limitations and uncertainties in the evidence base which warrant caution in its 
interpretation.  
 
Limitations of the RCT 
A key issue that may limit the robustness of the efficacy and safety data reported in the CS[6] related 
to the design of GADOLIN. In this open-label study, patients and investigators were all unblinded to 
the assigned treatment. Double-blinding protects against performance bias and measurement 
bias[16] and its absence in RCTs tends to result in larger treatment effects.[17] With many cytotoxic 
cancer drugs, the nature of the intervention precludes blinding (i.e. drug toxicities or manner of 
administration) for the practical and ethical reason that informed dose monitoring and adjustment is 
required. Although it is almost universally absent from oncology trials, blinded outcome assessment 
can enhance bias reduction.[18] 
 
Another issue that may have limited the robustness of the efficacy and safety data reported in the 
CS[6] related to the subgroup analysis of participants in GADOLINwith FL that were refractory to 
rituximab or a rituximab-containing regimen (the population defined in the marketing authorisation of 
obinutuzumab).  The study was not powered for this subgroup analysis and the protection for 
unknown confounders provided by randomisation may have been lost.  In addition to the known 
limitations of subgroup analyses,[19] further limitations of the subgroup include the slight imbalances 
of relevant prognostic factors (such as disease stage), small sample sizes and lack of statistical 
power to detect a clinically relevant difference between study groups.  As a result, these results 
should be treated with caution. In addition, GADOLIN was designed to assess PFS benefit after 
induction and maintenance treatment as a whole, so the relative contribution of each treatment phase 
was difficult to assess.  
 
Uncertainties generated by the evidence 
The main uncertainty in the evidence base related to the lack of any head-to-head RCTs comparing 
obinutuzumab in combination with bendamustine with other relevant interventions such as 
chemotherapy regimens without rituximab (other than bendamustine monotherapy) or best supportive 
care for the treatment of rituximab-refractory FL.  In addition, GADOLIN included a mixed population 
of three distinct subgroups of people with FL: people refractory to induction treatment with rituximab 
monotherapy, people refractory to induction treatment with rituximab-chemotherapy and people 
refractory during, or within 6 months of completing maintenance treatment with rituximab maintenance 
therapy.  In the UK, rituximab monotherapy is rarely used as induction treatment and people who 
relapse during or within six months of completing maintenance treatment with rituximab (after 
responding to rituximab in combination with chemotherapy) would typically be re-treated with 
ULWX[LPDE LQ FRPELQDWLRQ ZLWK DOWHUQDWLYH FKHPRWKHUDSLHV DQG ZRXOG QRW EH FRQVLGHUHG µWUXO\¶
refractory). As a result, in the UK, bendamustine monotherapy would mostly be considered an 
appropriate comparator in people refractory to induction treatment with rituximab-chemotherapy 
(where the chemotherapy used is not bendamustine). Although a few centres from the UK were 
included within the pivotal study, the subgroup populations of the GADOLIN trial are not an absolute 
reflection of the population with FL in the UK. Furthermore, as noted by Hamlin,[20] in current practice 
rituximab plus bendamustine is increasingly being used as a first-line treatment regimen, and as a 
result the relevance of GADOLIN to the UK is unclear, particularly in patients previously exposed to 
bendamustine.  
3.3. Cost-effectiveness evidence submitted by the company 
As part of its submission to NICE, the company submitted a model-based health economic analysis in 
Excel. The analysis was undertaken from the perspective of the UK National Health Service (NHS) 
and Personal Social Services (PSS) over a lifetime horizon. All costs and health outcomes were 
discounted at a rate of 3.5% per annum.[1] 
The economic analysis was based on the clinical effectiveness evidence for the FL subgroup of the 
population enrolled in GADOLIN[9-14] and assessed the cost-effectiveness of O-benda+O versus 
bendamustine monotherapy in adults with FL who did not respond or who progressed during or within 
6 months of completing treatment with rituximab.  
The company base-case model had three main health states; progression-free (separated into on- 
and off-treatment phase); progressed disease and death. The model adopted a semi-Markov 
approach whereby OS is estimated indirectly from PFS and post-progression survival (PPS). This 
approach was justified by the company owing to the immaturity of the OS data in GADOLIN and the 
indolent nature of the condition. 
Parametric survival functions (Weibull in the base-case) were fitted to PFS separately for each arm of 
GADOLIN. [9-14] Patients leaving the progression-free state who had not died before progression 
moved to the progressed disease state. Tunnel states were used to allow the probability of death in 
the progressed disease state to be dependent on time since progression. Parametric survival 
functions were fitted to post-progression data pooled across both arms of GADOLIN. The K-M 
survival function for time-to-off-treatment from GADOLIN was used to estimate the duration of 
treatment. 
The utility values were taken from a published UK study.[21] Resource use associated with the 
management of FL was derived from UK guidelines[5] and previous evaluations of treatments for 
FL.[22] 
An initial confidential patient access scheme (PAS), offering obinutuzumab at a discount price to the 
NHS ZDVSURYLGHGE\WKHFRPSDQ\7KHFRPSDQ\¶VGHWHUPLQLVWLFEDVH-case ICER was confidential. 
However, tKHFRPSDQ\¶VEDVH-case ICER did not vary greatly in the majority of the sensitivity and 
scenario analyses presented by the company, with the exception to changes in the survival functions 
used for PFS and PPS. 
3.4 Critique of the cost-effectiveness evidence and interpretation 
7KH(5*FULWLFDOO\DSSUDLVHGWKHFRPSDQ\¶VKHDOWKHFRQRPLFDQDO\Vis and the model upon which the 
analysis was based. As part of its critical appraisal, the ERG checked the calculations in the 
FRPSDQ\¶V HFRQRPLF PRGHO WR LGHQWLI\ DQ\ SURJUDPPLQJ HUURUV DQGRU LQFRQVLVWHQFLHV 1R PDMRU
SURJUDPPLQJHUURUVZHUHLGHQWLILHGLQWKHFRPSDQ\¶V model during this process. 
 
A key concern from the ERG was that the CS failed to provide a subgroup analysis according to 
whether patients were refractory to induction treatment with R-chemotherapy or were refractory 
during, or within 6 months of completing maintenance treatment with rituximab monotherapy. The 
ERG considered this to be an important limitation, as the population included in GADOLIN[9-14] was 
broader than the population that would be considered to be refractory in the UK and that would be 
eligible for bendamustine monotherapy. 
The ERG also raised concerns regarding the generalisability of people recruited in the trial to the UK 
setting, given that bendamustine in combination with rituximab is widely used in first-line treatment, 
therefore limiting the subsequent use of bendamustine in combination or not in later line of 
treatments. GADOLIN[9-14] also included a proportion of patients who were refractory to rituximab 
monotherapy, which is rarely used in the UK.  
The ERG further considered that the method used to estimate OS within the company model may 
have biased the cost-effectiveness estimates in favour of O-benda+O as it underestimates survival in 
the bendamustine arm when compared to the KM data from GADOLIN.  
7KH UHSUHVHQWDWLRQ RI WKH WUHDWPHQW SDWKZD\ LQ WKH FRPSDQ\¶V PRGHO Zas also considered to be 
overly-simplistic. The treatment pathway in FL is complex and may depend on the previous line of 
treatment, the time of relapse, DQGWKHSDWLHQW¶VFKDUDFWHULVWLFVDPRQJVWRWKHUIDFWRUV)RULQVWDQFH
allogeneic stem cell transplant was not considered despite being used in the UK in patients who are fit 
enough and who are in their second or subsequent remission.  
 
There was also uncertainty about the most appropriate parametric extrapolation for PFS and PPS and 
the assumption of constant pre-progression mortality. Utility values point estimates used in the 
economic model were also uncertain. The ERG further considered that utility values needed to be 
adjusted for age-related declines in utility.  
Finally, the ERG was concerned that the model did not adequately reflect subsequent lines of therapy 
for this population, particularly as a significant proportion were assumed to go on to rituximab-
containing regimens which seems unlikely in a rituximab refractory population. 
  
3.5 Additional work undertaken by the ERG 
 
A number of analyses were undertaken by the ERG which informed its preferred base-case. The main 
changes informing WKH(5*¶VSUHIHUUHGEDVH-case were:  
x the use of an alternative approach (a partitioned survival approach) to estimate OS  
x adjustment of utility by age 
x assuming a lower cost for subsequent treatments in post-progression 
x using the cost for generic bendamustine 
x amendment to drug administration costs 
x corrections of minor errors identified by the ERG 
 
,QWKH(5*¶VSDUWLWLRQHGVXUYLYDODSSURDFK the parametric survival functions fitted to the Kaplan-Meier 
(K-M) survival functions were used to estimate parametric OS survival functions for both arms. 
However, rather than assuming a life-time treatment effect, the OS survival function fitted to the O-
benda+O arm was only applied up to the last event (31 months) with the hazard of death predicted by 
the bendamustine monotherapy arm applied thereafter. The ERG considered it reasonable not to 
assume a life-time treatment effect given that the treatment duration was limited to 2.5 years 
(including both induction and maintenance therapy) and the OS data were still immature. 
,Q DGGLWLRQ WR WKH (5*¶V SUHIHUUHG EDVH-case conducted within the whole GADOLIN FL[9-14] 
population, the ERG undertook an exploratory analysis for the subgroup of people with FL refractory 
to R-chemotherapy induction. This analysis was conducted by the ERG as this was the subgroup 
most likely to be GHHPHGµWUXly¶refractory to rituximab and to be offered bendamustine monotherapy 
in England. Nevertheless, despite the relevance of this subgroup, the ERG cautioned that this was a 
non-randomised subgroup and that the analysis relied on a smaller sample size. 
3.6 Conclusion of the ERG report 
 
The ERG concluded that the efficacy (PFS) of obinutuzumab in combination with bendamustine was 
positively demonstrated (compared with bendamustine monotherapy) in GADOLIN,[9-14] and that its 
safety profile was acceptable.   
However, GADOLIN[9-14] had some issues with generalisability. In particular, the ERG did not 
consider the subgroup of people with FL refractory to induction treatment with rituximab monotherapy 
to be relevant to UK clinical practice as induction treatment with rituximab monotherapy is rarely used 
in the UK. Similarly, the ERG did not consider bendamustine monotherapy to be an appropriate 
comparator in people with FL who relapsed during or within 6 months of completing maintenance 
treatment with rituximab monotherapy (following successful induction with R-chemotherapy). 
The survival data on which the cost-effectiveness estimates were based were immature and this 
increased the uncertainty associated with the ICERs. A key concern from the ERG was the approach 
used by the company to estimate OS. The ERG considered that the method used to estimate OS 
within the company model may have biased the cost-effectiveness estimates in favour of O-benda+O 
as it underestimated survival in the bendamustine arm when compared to the K-M survival function 
IURP*$'2/,17KH(5*¶VDOWHUQDWLYHDSSURDFKSURYLGHGDEHWWHUILWWRWKHREVHUYHG26GDWDLQWKH
bendamustine arm without significantly altering the estimates for OS in the O-benda+O arm.  
ICERs were confidential but the ERG¶V alternative approach to model OS increased the ICER. 
3.7 Additional evidence submitted by the company in response to the ACD and comments from 
the ERG 
Following preliminary guidance in the ACD, the company submitted additional evidence to support the 
use of obinutuzumab in people with FL that is refractory to rituximab.[7]  
7KHFRPSDQ\¶VUHVSRQVHWRWKH$&'LQFOXGHGERWKORQJHU-term follow-up data from GADOLIN and a 
revised economic model. The company also proposed a revised PAS. 
The company provided updated clinical effectiveness and safety results from GADOLIN using a data 
cut-off of 1st April 2016; however, these results were academic in confidence and cannot be 
reproduced here.   
The revised economic model submitted after the ACD used a partitioned survival approach as 
recommended by the ERG, but the survival functions for OS were fitted to the updated data and the 
OS survival function for O-benda+O was applied up to the longest observed follow up period (5.5 
years) rather than the last observed event (4.0 years). Different durations of treatment effect (4.0 
years, 7 years and life-time) were explored in sensitivity analyses. The following changes were also 
made: 
x Use of PFS assessed by investigator (second of secondary endpoint) instead of PFS 
assessed by IRC based on latest data-cut from GADOLIN, 
x Updated data on time on treatment and adverse events based on latest data-cut from the 
GADOLIN trial, 
x Use RI(5*¶VSreferred assumptions (see section 3.5)  
x Use of separate utility values for patients on and off treatment in the progression-free state 
based on data from GADOLIN. 
 
The ERG considered that the updated analysis of GADOLIN confirmed the benefits of O-benda-O 
versus bendamustine monotherapy. 
However, a key concern from the ERG was not addressed in that results were only presented for the 
whole subgroup of people with FL from GADOLIN rather than the subgroup refractory to R-
chemotherapy induction. 
The ERG was generally satisfied with the approach taken by the company in the revised economic 
model, but noted the assumption made by the company about the duration of the treatment effect. A 
small inconsistency was also identified by the ERG and was subsequently corrected. 
 
4. Key Methodological Issues 
The key methodological issue in this appraisal was the approach to model OS given the immaturity of 
the GADOLIN trial data. The company used a semi-Markov model whereby OS was estimated 
indirectly from PFS and PPS. However, this approach provided a poor fit to the bendamustine 
monotherapy arm. Whilst the ERG considered the use of a semi-Markov approach to be generally 
acceptable, the ERG highlighted that the choice of modelling approach should be guided by the 
quality of the data available and the face validity of the model. 
In light of this, the ERG suggested an alternative modelling approach; the partitioned survival model. 
The ERG considered that a partitioned survival approach provided a more realistic OS survival 
functions for both arms.  
 When using the partitioned survival model, a decision has to be made whether patients are assumed 
to follow the parametric survival function which has been fitted to the trial data for their whole life-time, 
which is equivalent to assuming a life-long treatment effect, or whether the treatment effect observed 
in the trial is assumed to end at some point. In this case the ICERs were very sensitive to the duration 
of treatment effect assumed when extrapolating OS, suggesting that the collection of further evidence 
to quantify long-term OS would be necessary.   
 
5. NICE guidance 
In July 2017, on the basis of the evidence available, the NICE AC produced the following final 
guidance to the NHS in England (TA472).[3] Obinutuzumab in combination with bendamustine 
followed by obinutuzumab maintenance is recommended for use within the Cancer Drugs Fund as an 
option for treating follicular lymphoma that did not respond or progressed during or up to 6 months 
after treatment with rituximab or a rituximab-containing regimen, only if the conditions in the managed 
access agreement for obinutuzumab are followed.[3] 
 
The committee discussed the population included in GADOLIN and concluded that the most relevant 
population was people with disease that is refractory to induction with R-chemotherapy, or who 
relapse early-on during rituximab maintenance. Clinical experts echoed the view from the ERG that 
induction treatment with rituximab monotherapy was not the current standard of care in England, 
although the committee KHDUG WKDW WKLV PD\ FKDQJH IROORZLQJ WKH UHFHQW SXEOLFDWLRQ RI 1,&(¶V
guidance on NHL. The committee agreed that the population who might be offered obinutuzumab in 
combination with bendamustine was potentially broader than those people with R-chemotherapy 
refractory disease and therefore would not limit its consideration to this subgroup. 
 
The committee discussed the clinical effectiveness from GADOLIN and noted an improvement in 
progression-free survival despite the lack of difference in response rate at the end of induction. The 
committee was unclear whether the improvement in progression-free survival was attributable to the 
inclusion of a maintenance phase for obinutuzumab or a better type of response in the intervention 
arm (as shown using data on minimum residual disease).[3] 
 
The committee discussed the relationship between PFS and OS, but noted that because of the 
immaturity of the data, the relationship was unclear. Longer follow-up data submitted by the company 
after the ACD were considered relevant by the committee,[3] but the committee felt that the 
magnitude of any survival gain remained uncertain. 
 
The committee considered the revised company base-case which used the alternative modelling 
approach suggested by the ERG and noted that the ICER was very sensitive to the assumption 
regarding the duration of treatment effect on overall survival. The committee noted that the ICERs 
were above what is normally considered a cost-effective use of NHS resources when the duration of 
treatment effect was assumed to be less than 7 years. Given the large uncertainty, the committee 
concluded that because the duration of treatment effect on overall survival was the main driver in the 
model, the cost-effectiveness should be based on the final analysis of GADOLIN which is expected to 
be reported in 2019.[3] 
 
The committee concluded that O-Benda-O could not be recommended for routine use as the 
company and ERG base-case ICERs were above the level that could be accepted. However, given 
the possibility for O-Benda-O to be cost-effective when more mature OS data becomes available, the 
committee discussed whether it could be recommended within the Cancer Drug Fund. Under this 
DUUDQJHPHQW³GUXJVWKDWDSpear promising, but for which the evidence is not robust enough, may be 
given a conditional recommendation by NICE and made available to NHS through the Cancer Drugs 
)XQG´[3] 
The committee noted that scenario analyses conducted by the company suggested that O-Benda-O 
had the potential to be considered cost-effective when the treatment duration effect on overall survival 
was increased alongside the revised PAS. The committee re-iterated the immaturity of the data and 
noted that more mature data, which are expected in a few years, would produce a more robust cost-
effectiveness estimate and resolve the uncertainty around the duration of treatment effect.  
In conclusion, the committee decided to recommend O-Benda+O within the CDF for the population 
covered by the marketing authorisation until NICE is able to review the guidance based on the final 
analyses from GADOLIN.[3] 
 6. Conclusions 
Efficacy for PFS was demonstrated in GADOLIN. Data on OS were promising but immature. The cost-
effectiveness estimate was largely dependent upon the duration of treatment effect on overall survival 
and the committee concluded that the cost-effectiveness should be based on the final analysis of 
GADOLIN, but recommended obinutuzumab within the CDF for the population covered by the 
marketing authorisation until the final analyses from GADOLIN are available. 
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